FibroGen receives $6.4M holdback payment from AstraZeneca on China sale

KYNTRA BIO, INC.

Received $6.4M from AstraZeneca, satisfying $6.0M first holdback plus $0.4M net cash adjustment.
China operations sale closed Aug 29, 2025; total consideration ~$220M ($85M enterprise + ~$135M net cash).
$210M paid at closing; $4.0M second holdback for indemnity claims remains, releasable nine months post-close.
Payment marks release of first post-closing holdback under February 2025 share purchase agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.